Track topics on Twitter Track topics that are important to you
This is a multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.
Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
guaifenesin (Mucinex), placebo
Pioneer Clinical Research
Reckitt Benckiser Inc.
Published on BioPortfolio: 2014-08-27T03:16:46-0400
Demonstrate bioequivalence of guaifenesin in Mucinex® extended release (ER) 600 mg tablet in normal healthy volunteers compared to the immediate release guaifenesin 200 mg tablet referenc...
Evaluate the pharmacokinetics (PK), Safety and tolerability of guaifenesin (Mucinex®) in an immediate-release formulation when a single dose is administered in adolescents and in adults w...
Determine bioequivalence, safety and tolerability of guaifenesin extended-release 600 mg (Mucinex® SE) compared to an immediate-release syrup reference product in normal healthy subjects.
Characterize and assess PK of guaifenesin in Mucinex® 1200 mg ER Bi-Layer Tablet
The objective of the study is to evaluate the safety and efficacy of Mucinex D tablets in providing symptom relief when administered as an adjunct to antibiotic therapy in patients with ac...
We report an improvement in symptoms and quality of life with long-term use of guaifenesin for the treatment of mucus-related symptoms in a patient with chronic bronchitis, who presented with mucus hy...
Common cold is a frequent upper respiratory tract infection, but the role of ambient temperature in the infection is unclear.
Roasted barley extract (mugi-cha) containing cyclo (D-Phe-L-Pro) prevents lowering of cutaneous blood flow and skin temperature under air-conditioning - A randomized, double-blind, placebo-controlled, crossover study.
Roasted barley extract (RBE), also known as mugi-cha, is a well-known healthy non-caffeinated beverage and its health functionality has been widely reported. Our previous clinical study showed that RB...
It is well known that cold environments are predominant over the Earth and there are a great number of reports analyzing bacterial adaptations to cold. Most of these works are focused on characteristi...
This study examined self-paced, high-intensity exercise during mild hypothermia and whether hyperoxia may offset any potential impairment. Twelve trained males each completed 15 km time trials in thre...
A broad category of multi-ingredient preparations that are marketed for the relief of upper respiratory symptoms resulting from the COMMON COLD; ALLERGIES; or HUMAN INFLUENZA. While the majority of these medications are available as OVER-THE-COUNTER DRUGS some of them contain ingredients that require them to be sold as PRESCRIPTION DRUGS or as BEHIND-THE COUNTER DRUGS.
A genus of PICORNAVIRIDAE inhabiting primarily the respiratory tract of mammalian hosts. It includes over 100 human serotypes associated with the COMMON COLD.
A catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing.
An expectorant that also has some muscle relaxing action. It is used in many cough preparations.
Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase 'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...